Benicar, a olmesartan angiotensin II receptor blocker (ARB), is a medication approved for the treatment of high blood pressure alone or with other antihypertensive agents. Benicar was approved by the FDA in 2002 and is distributed by Daiichi Sankyo of Forest Laboratories.
In May 2012, the Mayo Clinic published a study of 22 cases involving Benicar. Each patient in the study was using Benicar and being treated for symptoms of Celiac disease. Once the patients discontinued their use of Benicar, the symptoms of Celiac disease ceased.
In July 2013, the FDA issued a safety announcement for olmestartan medoxomil (Benicar, Benicar HCT, Azor, Tribenzor) and its link to sprue-like enteropathy. In the announcement, they required labeling changes to reflect health risks. At the time of the statement, the FDA did not link any of the 8 other angiotensin II receptor blockers to sprue-like enteropathy.
Sprue-like enteropathy is a serious health condition that sometimes requires hospitalization. Symptoms include:
According to the FDA, the condition can develop well after Benicar (olmesartan) is taken, with symptoms developing months or even years after a patient starts taking the drug. Anyone displaying symptoms of sprue-like enteropathy should see a medical professional immediately.
If you or a loved one has suffered any of the following conditions, you may be eligible for a Benicar lawsuit:
Please contact our legal team as soon as possible for a free, no obligation consultation.